Literature DB >> 23890060

The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures.

Jérôme Galon1, Helen K Angell, Davide Bedognetti, Francesco M Marincola.   

Abstract

Numerous analyses of large patient cohorts identified specific patterns of immune activation associated with patient survival. We established these as the immune contexture, encompassing the type, functional orientation, density, and location of adaptive immune cells within distinct tumor regions. Based on the immune contexture, a standardized, powerful immune stratification system, the Immunoscore, was delineated. The immune contexture is characterized by immune signatures also observed in association with the broader phenomenon of immune-mediated, tissue-specific destruction. We defined these as the immunologic constant of rejection. Predictive, prognostic, and mechanistic immune signatures overlap, and a continuum of intratumor immune reactions exists. The balance between tumor cell growth and elimination may be tipped upon a crescendo induced by immune manipulations aimed at enhancing naturally occurring immunosurveillance. Here, we propose a broader immunological interpretation of these three concepts--immune contexture, Immunoscore, and immunologic constant of rejection--that segregates oncogenic processes independently of their tissue origin.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23890060     DOI: 10.1016/j.immuni.2013.07.008

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  339 in total

1.  High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer.

Authors:  Ryan O Emerson; Anna M Sherwood; Mark J Rieder; Jamie Guenthoer; David W Williamson; Christopher S Carlson; Charles W Drescher; Muneesh Tewari; Jason H Bielas; Harlan S Robins
Journal:  J Pathol       Date:  2013-12       Impact factor: 7.996

2.  Lymphopenia after induction chemotherapy correlates with incomplete surgical resection in patients with advanced ovarian cancer.

Authors:  Yasunori Yoshino; Ayumi Taguchi; Maki Takao; Tomoko Kashiyama; Akiko Furusawa; Masaya Uno; Satoshi Okada; Nao Kino; Toshiharu Yasugi
Journal:  Int J Clin Oncol       Date:  2018-11-30       Impact factor: 3.402

Review 3.  Microbiota modulation of myeloid cells in cancer therapy.

Authors:  Romina S Goldszmid; Amiran Dzutsev; Sophie Viaud; Laurence Zitvogel; Nicholas P Restifo; Giorgio Trinchieri
Journal:  Cancer Immunol Res       Date:  2015-02       Impact factor: 11.151

4.  T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors.

Authors:  Jiemiao Hu; Chuang Sun; Chantale Bernatchez; Xueqing Xia; Patrick Hwu; Gianpietro Dotti; Shulin Li
Journal:  Clin Cancer Res       Date:  2018-02-01       Impact factor: 12.531

5.  Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma.

Authors:  Robyn D Gartrell; Douglas K Marks; Emanuelle M Rizk; Margaret Bogardus; Camille L Gérard; Luke W Barker; Yichun Fu; Camden L Esancy; Gen Li; Jiayi Ji; Shumin Rui; Marc S Ernstoff; Bret Taback; Sarabjot Pabla; Rui Chang; Sandra J Lee; John J Krolewski; Carl Morrison; Basil A Horst; Yvonne M Saenger
Journal:  Clin Cancer Res       Date:  2019-01-15       Impact factor: 12.531

6.  Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes.

Authors:  Patrick H Lizotte; Elena V Ivanova; Mark M Awad; Robert E Jones; Lauren Keogh; Hongye Liu; Ruben Dries; Christina Almonte; Grit S Herter-Sprie; Abigail Santos; Nora B Feeney; Cloud P Paweletz; Meghana M Kulkarni; Adam J Bass; Anil K Rustgi; Guo-Cheng Yuan; Donald W Kufe; Pasi A Jänne; Peter S Hammerman; Lynette M Sholl; F Stephen Hodi; William G Richards; Raphael Bueno; Jessie M English; Mark A Bittinger; Kwok-Kin Wong
Journal:  JCI Insight       Date:  2016-09-08

7.  Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases.

Authors:  Ileana S Mauldin; Nolan A Wages; Anne M Stowman; Ena Wang; Mark E Smolkin; Walter C Olson; Donna H Deacon; Kelly T Smith; Nadedja V Galeassi; Kimberly A Chianese-Bullock; Lynn T Dengel; Francesco M Marincola; Gina R Petroni; David W Mullins; Craig L Slingluff
Journal:  Cancer Immunol Immunother       Date:  2016-08-13       Impact factor: 6.968

8.  Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases.

Authors:  Ileana S Mauldin; Nolan A Wages; Anne M Stowman; Ena Wang; Walter C Olson; Donna H Deacon; Kelly T Smith; Nadedja Galeassi; Jessica E Teague; Mark E Smolkin; Kimberly A Chianese-Bullock; Rachael A Clark; Gina R Petroni; Francesco M Marincola; David W Mullins; Craig L Slingluff
Journal:  Cancer Immunol Immunother       Date:  2016-08-13       Impact factor: 6.968

9.  Identification and Characterization of Tertiary Lymphoid Structures in Murine Melanoma.

Authors:  Anthony B Rodriguez; J David Peske; Victor H Engelhard
Journal:  Methods Mol Biol       Date:  2018

10.  CD169 identifies an activated CD8(+) T cell subset in regional lymph nodes that predicts favorable prognosis in colorectal cancer patients.

Authors:  Jiali Zhang; Jing Xu; Rong-Xin Zhang; Yi Zhang; Qing-Jian Ou; Jin-Qing Li; Ze-Zhou Jiang; Xiao-Jun Wu; Yu-Jing Fang; Limin Zheng
Journal:  Oncoimmunology       Date:  2016-04-29       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.